Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea pigs.
作者信息
Ho R J, Burke R L, Merigan T C
机构信息
Department of Medicine, Stanford University School of Medicine, California 94305.
出版信息
J Virol. 1989 Jul;63(7):2951-8. doi: 10.1128/JVI.63.7.2951-2958.1989.
Abstract
The therapeutic and immunologic effects of a liposome preparation containing both a macrophage activator, muramyl-tripeptide-phosphatidylethanolamine, and a recombinant antigen, glycoprotein D of herpes simplex virus type 1, have been investigated. This preparation was tested in vitro for the ability to stimulate peripheral blood lymphocytes and in vivo for the control of recurrent herpes genitalis in guinea pigs. Our results show that the liposome-antigen-adjuvant preparation is capable of enhancing antigen-specific lymphocyte stimulation, which may be related to the observed 75% suppression of the frequency and severity of reactivation of recurrent herpes simplex virus type 2 genitalis compared with that of placebo controls.
摘要
相似文献
1
Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea pigs.
J Virol. 1989 Jul;63(7):2951-8. doi: 10.1128/JVI.63.7.2951-2958.1989.
2
Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide.
Science. 1985 Apr 26;228(4698):495-7. doi: 10.1126/science.2984772.
3
Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy.
Antiviral Res. 1989 May-Jun;11(4):203-14. doi: 10.1016/0166-3542(89)90005-3.
4
Disposition of antigen-presenting liposomes in vivo: effect on presentation of herpes simplex virus antigen rgD.
Vaccine. 1994;12(3):235-42. doi: 10.1016/0264-410x(94)90200-3.
5
Physical and biological characterization of antigen presenting liposome formulations: relative efficacy for the treatment of recurrent genital HSV-2 in guinea pigs.
Antiviral Res. 1990 Apr;13(4):187-99. doi: 10.1016/0166-3542(90)90037-8.
6
Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection.
Vaccine. 1994;12(3):200-9. doi: 10.1016/0264-410x(94)90195-3.
7
The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine.
J Immunol. 1988 Sep 1;141(5):1720-7.
8
The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine.
J Infect Dis. 1994 Nov;170(5):1110-9. doi: 10.1093/infdis/170.5.1110.
9
Enhancement of host resistance against virus infections by MTP-PE, a synthetic lipophilic muramyl peptide--I. Increased survival in mice and guinea pigs after single drug administration prior to infection, and the effect of MTP-PE on interferon levels in sera and lungs.
Int J Immunopharmacol. 1986;8(8):931-42. doi: 10.1016/0192-0561(86)90095-0.
10
Herpes simplex virus glycoprotein treatment of recurrent genital herpes.
J Infect Dis. 1988 Jan;157(1):156-63. doi: 10.1093/infdis/157.1.156.
引用本文的文献
1
Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.
J Virol. 2005 Jan;79(1):410-8. doi: 10.1128/JVI.79.1.410-418.2005.
2
Herpes simplex virus type 2 vaccines: new ground for optimism?
Clin Diagn Lab Immunol. 2004 May;11(3):437-45. doi: 10.1128/CDLI.11.3.437-445.2004.
3
Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits.
J Virol. 1994 Aug;68(8):5084-92. doi: 10.1128/JVI.68.8.5084-5092.1994.
4
Molecular adjuvants and immunomodulators: new approaches to immunization.
Clin Microbiol Rev. 1994 Jul;7(3):277-89. doi: 10.1128/CMR.7.3.277.
5
Liposomes as delivery systems in the prevention and treatment of infectious diseases.
Pharm World Sci. 1995 Jan 27;17(1):1-11. doi: 10.1007/BF01875551.
6
Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system.
J Virol. 1990 Jun;64(6):2653-9. doi: 10.1128/JVI.64.6.2653-2659.1990.
7
Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies.
Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10527-31. doi: 10.1073/pnas.89.21.10527.
本文引用的文献
1
Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages.
J Immunol. 1980 Dec;125(6):2454-60.
2
Muramyl peptides. Chemical structure, biological activity and mechanism of action.
Mol Cell Biochem. 1981 Dec 4;41:27-47. doi: 10.1007/BF00225295.
3
Marked increase in Ia-bearing macrophages during Trypanosoma cruzi infection.
Clin Immunol Immunopathol. 1981 May;19(2):190-5. doi: 10.1016/0090-1229(81)90062-3.
4
gamma Interferon production appears to predict time of recurrence of herpes labialis.
J Immunol. 1983 May;130(5):2397-400.
5
Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects.
N Engl J Med. 1983 Apr 21;308(16):916-21. doi: 10.1056/NEJM198304213081602.
6
A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection.
N Engl J Med. 1984 Jun 14;310(24):1551-6. doi: 10.1056/NEJM198406143102402.
7
Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir.
N Engl J Med. 1984 Jun 14;310(24):1545-50. doi: 10.1056/NEJM198406143102401.
8
Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease.
J Infect Dis. 1982 Sep;146(3):397-404. doi: 10.1093/infdis/146.3.397.
9
Acyclovir prophylaxis of recurrent genital herpes: randomised placebo controlled crossover study.
Genitourin Med. 1985 Dec;61(6):387-90. doi: 10.1136/sti.61.6.387.
10
A novel method for encapsulation of macromolecules in liposomes.
Biochim Biophys Acta. 1985 Jun 11;816(1):1-8. doi: 10.1016/0005-2736(85)90386-4.
Zotero 插件